ATE300947T1 - Behandlung von erkrankungen mit zystenbildung - Google Patents

Behandlung von erkrankungen mit zystenbildung

Info

Publication number
ATE300947T1
ATE300947T1 AT99966268T AT99966268T ATE300947T1 AT E300947 T1 ATE300947 T1 AT E300947T1 AT 99966268 T AT99966268 T AT 99966268T AT 99966268 T AT99966268 T AT 99966268T AT E300947 T1 ATE300947 T1 AT E300947T1
Authority
AT
Austria
Prior art keywords
treatment
diseases involving
cyst formation
diagnosis
involving cyst
Prior art date
Application number
AT99966268T
Other languages
English (en)
Inventor
George F Schreiner
Alison Joly
R Tyler White
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE300947T1 publication Critical patent/ATE300947T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99966268T 1998-12-18 1999-12-15 Behandlung von erkrankungen mit zystenbildung ATE300947T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11300898P 1998-12-18 1998-12-18
US13620899P 1999-05-26 1999-05-26
PCT/US1999/029763 WO2000037085A1 (en) 1998-12-18 1999-12-15 Treatment of diseases involving cyst formation

Publications (1)

Publication Number Publication Date
ATE300947T1 true ATE300947T1 (de) 2005-08-15

Family

ID=26810615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966268T ATE300947T1 (de) 1998-12-18 1999-12-15 Behandlung von erkrankungen mit zystenbildung

Country Status (7)

Country Link
US (2) US6380183B1 (de)
EP (1) EP1140106B1 (de)
AT (1) ATE300947T1 (de)
AU (1) AU2185000A (de)
DE (1) DE69926535T2 (de)
ES (1) ES2246588T3 (de)
WO (1) WO2000037085A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035038A4 (de) * 2006-04-03 2011-04-06 Stowers Inst For Medical Res Zusammensetzungen und verfahren zur behandlung von polyzystischer nierenerkrankung
US8429516B1 (en) * 2007-08-20 2013-04-23 Adobe Systems Incorporated Media player feedback
RU2505315C2 (ru) * 2008-07-30 2014-01-27 Нитто Денко Корпорейшн Носители лекарственных средств
CA2779161A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
EP3037518B1 (de) 2014-12-28 2020-05-06 Femtobiomed Inc. Vorrichtung zum einbringen von material in eine zelle
WO2019222559A1 (en) * 2018-05-16 2019-11-21 University Of Washington High-throughput automation of organoids for identifying therapeutic strategies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2599740B1 (fr) 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5789189A (en) 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
EP0663958A4 (de) 1992-09-25 1999-10-20 Woo David D L The Regents Of T Hemmung der bildung von zysten mittels zytosklettspezifischer arzneimittel.
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
FR2785803B1 (fr) * 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
WO2001051922A2 (en) * 2000-01-14 2001-07-19 Mitokor Identification of peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
DE69926535D1 (de) 2005-09-08
US20030008864A1 (en) 2003-01-09
AU2185000A (en) 2000-07-12
WO2000037085A1 (en) 2000-06-29
ES2246588T3 (es) 2006-02-16
DE69926535T2 (de) 2006-03-30
US6380183B1 (en) 2002-04-30
EP1140106B1 (de) 2005-08-03
EP1140106A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
BR9912053A (pt) Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DK0841949T3 (da) Anvendelse af saccharid-konjugater
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE60033649D1 (de) Verbindungen und therapeutische methoden
PT815087E (pt) Derivados de fenilo trissubstituidos
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ATE300947T1 (de) Behandlung von erkrankungen mit zystenbildung
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
NO20005548D0 (no) Mykobakterieinhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties